Neuro

Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022

Retrieved on: 
Thursday, May 5, 2022
Neuro, COVID-19, Q&A, HDS, GLOBE, DME, Johns Hopkins University, HDT, Diabetic retinopathy, Inflammation, Therapy, Neurology, Disease, News, Conference, CEO, Technology, AMD, Pharmaceutical industry, Ashvattha, Ophthalmology

REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics, (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President of Ashvattha, will provide a corporate overview followed by a moderated Q&A at the UBS Global Healthcare Conference 2022 taking place in New York, NY, May 23-25, 2022.

Key Points: 
  • REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics, (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President of Ashvattha, will provide a corporate overview followed by a moderated Q&A at the UBS Global Healthcare Conference 2022 taking place in New York, NY, May 23-25, 2022.
  • Additional details can be found below:
    A webcast from the presentation may be accessed on the News page of the Ashvattha website following the event.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.
  • HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration

Retrieved on: 
Tuesday, May 3, 2022
Board, Neuro, NEI, CRADA, Historical annual reformulations of the influenza vaccine, IND, Biotechnology, Good laboratory practice, Pharmacokinetics, Development, Toxicity, Company, Securities Exchange Act of 1934, Metformin, Rabies, Securities Act of 1933, Judgement, BOCA, CD56, Cooperative research and development agreement, Review, Degenerative disease, OTC, Neoplasm, National Eye Institute, Drug Quality and Security Act, Laboratory, GLP, Vaccine, Infection, AMD, OTC Markets Group, Pharmaceutical industry

BOCA RATON, Fla., May 3, 2022 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into its Good Laboratory Practice (GLP) toxicology study.

Key Points: 
  • The Good Laboratory Practice (GLP) toxicology study is a requirement for an FDA Investigational New Drug (IND) filing.
  • Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute (NEI) and Curative Biotechnology, Inc. will collaborate to evaluate Curative's proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.
  • Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.

Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration

Retrieved on: 
Tuesday, May 3, 2022
Board, Neuro, NEI, CRADA, Historical annual reformulations of the influenza vaccine, IND, Biotechnology, Good laboratory practice, Pharmacokinetics, GLOBE, Toxicity, Development, Company, Securities Exchange Act of 1934, Metformin, Rabies, Securities Act of 1933, Judgement, CD56, Cooperative research and development agreement, Review, Degenerative disease, OTC, Neoplasm, National Eye Institute, Drug Quality and Security Act, Laboratory, GLP, Vaccine, Infection, AMD, OTC Markets Group, Pharmaceutical industry

Boca Raton, FL, May 03, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into its Good Laboratory Practice (GLP) toxicology study.

Key Points: 
  • The Good Laboratory Practice (GLP) toxicology study is a requirement for an FDA Investigational New Drug (IND) filing.
  • Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute (NEI) and Curative Biotechnology, Inc. will collaborate to evaluate Curatives proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.
  • Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.

ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Retrieved on: 
Tuesday, May 3, 2022
Communication, Johns Hopkins School of Medicine, Neuroinflammation, Public expenditure, Spanish, Kabuki syndrome, Person, ESCAPE, Aggression, Mercado, Gene, Forward-looking statement, Mission statement, AD, Epigenetics, COVID-19, MLL2, Schizophrenia, Patient, Clinical trial, Prospectus, Lewis Milestone, CNMV, Moderate, Amnesia, Degenerative disease, EVOLUTION, Genomics, Genetics, LSD1, ORY, Mouse, Lists of diseases, Kennedy Krieger Institute, Time, Neurology, ISIN, Borderline personality disorder, Sale, Ageing, Pediatrics, Neuro, GLOBE, Government budget balance, CNS, Johns Hopkins University, MS, Intellectual disability, Chromatin, Multiple sclerosis, Pharmaceutical industry, KMT2D

Kabuki syndrome (KS) is an autosomal dominant/X-linked disorder that affects multiple organ systems including neuro, immune, auditory and cardiac systems.

Key Points: 
  • Kabuki syndrome (KS) is an autosomal dominant/X-linked disorder that affects multiple organ systems including neuro, immune, auditory and cardiac systems.
  • Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European leader in epigenetics.
  • In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases.
  • Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon.

Ad-Tech Medical Welcomes Healthcare Industry Veteran Drew Rannells to lead Expansion into Intraoperative Neuromonitoring

Retrieved on: 
Tuesday, May 3, 2022
Hi-Tech Medical College, Rourkela, Neuro, ArchiMate, Elective surgery, Brain, OAK, Engineering, Butler University, Daily Journal Corporation, Electrode, Patient, Association of British HealthTech Industries, Caregiver, Leadership, Adoption, Tech, Surgeon, Drew, Medical device, Medicine

OAK CREEK, Wis., May 3, 2022 /PRNewswire/ -- Ad-Tech Medical, a portfolio company of ArchiMed, today announced that Drew Rannells has joined Ad-Tech's sales team. With more than 18-years' experience in healthcare industry sales leadership, Mr. Rannells will be concentrating on the expansion of Ad-Tech's presence in the Intraoperative Neuromonitoring market.

Key Points: 
  • OAK CREEK, Wis., May 3, 2022 /PRNewswire/ -- Ad-Tech Medical , a portfolio company of ArchiMed , today announced that Drew Rannells has joined Ad-Tech's sales team.
  • With more than 18-years' experience in healthcare industry sales leadership, Mr. Rannells will be concentrating on the expansion of Ad-Tech's presence in the Intraoperative Neuromonitoring market.
  • Drew's clinical know-how and patient focus will be a big asset to us and our customers, especially in neuromonitoring.
  • Mr. Rannells added, "I couldn't be more delighted about becoming a part of the distinguished team at Ad-Tech.

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Retrieved on: 
Monday, May 2, 2022
Neuro, COVID-19, VEGF, Volunteering, Microglia, CNV, HDS, Choroidal neovascularization, Toxicity, DME, GLOBE, Johns Hopkins University, Safety, ARVO, Research, Eye, CO, Patient, Intravitreal injection, Ashvattha, Association, Animal, HDT, Macrophage, Diabetic retinopathy, Inflammation, Human, Therapy, Association for Research in Vision and Ophthalmology, Neurology, RPE, Covalent bond, Disease, Liver, CEO, Technology, AMD, Annual general meeting, Pathology, VEGFR, Cell, Pharmaceutical industry, Vaccine, Ophthalmology, Ophthalmology

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced the presentation of safety data from a Phase 1 study of its lead candidate D-4517.2, a potent VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, CO, May 2-4, 2022.

Key Points: 
  • The data showed that single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects at dose levels of 0.25 mg/kg, 0.50 mg/kg and 1.0 mg/kg.
  • Current treatments for wet AMD and DME, degenerative retinal diseases, require invasive, intravitreal injections into the eye, which can be a treatment burden on patients and doctors.
  • The Phase 1 study of healthy human volunteers was conducted in three cohorts of 0.25 mg/kg, 0.50 mg/kg and 1.0 mg/kg subcutaneous doses.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Brain Cancer Canada funds Canada's first genomics technology for rapid and precise brain tumour diagnostics

Retrieved on: 
Sunday, May 1, 2022
Partnership, Adult, Cancer Care Ontario, Medicine, St. Michael's Hospital (Toronto), Program, Cancer, Awareness, Patient, Neoplasm, GLOBE, Technology, Central nervous system, Brain tumor, Goal, St. Michael's Hospital, Science, Brain, Precision medicine, Research, Hospital, Mortality, Neuro, Disease, Adolescence, Michael (archangel), Medical imaging

On this day Brain Cancer Canada grants $100,000to the St. Michael's Hospital program to acquire and develop genome technology helping brain cancer patients.

Key Points: 
  • On this day Brain Cancer Canada grants $100,000to the St. Michael's Hospital program to acquire and develop genome technology helping brain cancer patients.
  • This technology helps St. Michael's Hospital lead in a new frontier for precision medicine targeting pediatric and adult brain cancers.
  • "It is unfortunate that our work is needed to enable funding for cutting-edge technology in Canada in the fight against brain cancer.
  • To learn more about Brain Cancer Canada, please visit www.braincancercanada.ca
    For inquiries, please contact: Marc Peeters, Director Partnerships and Stakeholders at Brain Cancer Canada, [email protected] , 416 918 6678

TeDan Surgical Innovations Reimagines Anterior to the Psoas Access with the Release of the Phantom UL ZeroATP® Surgical Access System

Retrieved on: 
Thursday, April 28, 2022
Patent, TSI, Phantom, Association, Spine, American Association, Supine position, Neuro, ATP, Safety, Dentistry

SUGAR LAND, Texas, April 28, 2022 /PRNewswire/ -- TeDan Surgical Innovations (TSI), honors its commitment to improving the surgeon experience with its latest market release of the Phantom UL ZeroATP Surgical Access System.

Key Points: 
  • SUGAR LAND, Texas, April 28, 2022 /PRNewswire/ -- TeDan Surgical Innovations (TSI), honors its commitment to improving the surgeon experience with its latest market release of the Phantom UL ZeroATP Surgical Access System.
  • Keeping surgical access simplicity top of mind, ZeroATP reimagines lumbar access with ground-breaking single-system access from L2 to L5.
  • The launch of the Phantom UL ZeroATP Surgical Access System pioneers an innovative approach to the surgical corridor anterior to the psoas muscle.
  • To learn more about TSI's Phantom UL ZeroATP Surgical Access System visit https://youtu.be/L1WFqHzIW_Q or call 877-726-0886.

FDA Grants 510(k) Clearance to Onera STS, a System for At-Home and In-Lab Polysomnography Studies

Retrieved on: 
Thursday, April 28, 2022
Technology, Managed Care, Medical Devices, Hospitals, Science, Clinical Trials, FDA, Biotechnology, Alternative Medicine, Health, Other Science, Research, Software, Internet, Mobile, Wireless, Hardware, Data Management, US Foods, Sleep, CEO, Patient, FDA, Idiopathic hypersomnia, Food, Quality of life, Health, Jazz Pharmaceuticals, Diagnosis, Hospital, Multimedia, Physician, Stanford University Medical Center, Trial of the century, Neuro, Narcolepsy, PSG, Medical device, Pharmaceutical industry, Medicine, Polysomnography, ONERA

The FDA determined that Oneras product was substantially equivalent to a system widely used in todays in-lab PSG studies, marketed by the medical device manufacturer Natus Medical Inc.

Key Points: 
  • The FDA determined that Oneras product was substantially equivalent to a system widely used in todays in-lab PSG studies, marketed by the medical device manufacturer Natus Medical Inc.
  • Achieving FDA clearance is an exciting and critical milestone to our commitment to helping our customers deliver better access to care for their patients, says Ruben de Francisco, Founder and CEO of Onera.
  • Our end-to-end solution has the potential to improve the sleep and ultimately overall health of millions of patients, explains de Francisco.
  • Onera Health will present its latest clinical study results at SLEEP 2022, from 4th-8th June 2022 in Charlotte, NC.

Champion the Challenges Founder Deb Shaw Receives 2022 Stroke Survivor Hero Award

Retrieved on: 
Thursday, April 28, 2022
Plaque, Medicine, Awareness, ER, Family, Association, PONS, Stroke, Cardiovascular disease, American Heart Association, Health care, No, Philosophy, LOS, ICU, Rehabilitation, Stroke Heroes Act FAST, Neuro, Friends, Survivor, Shaw, Good Samaritan Hospital, Challenge, Sleep, Face, Social media, Survivor: Heroes vs. Villains, Founder, Pharmaceutical industry

LOS GATOS, Calif., April 28, 2022 /PRNewswire/ -- The American Stroke Association has bestowed its annual Stroke Survivor Hero Award to Deb Shaw, a three-time stroke survivor and the Founder and President of Champion the Challenges, a nonprofit foundation committed to helping inspire and motivate stroke survivors and their families to persevere during this life challenge.

Key Points: 
  • LOS GATOS, Calif., April 28, 2022 /PRNewswire/ -- The American Stroke Association has bestowed its annual Stroke Survivor Hero Award to Deb Shaw, a three-time stroke survivor and the Founder and President of Champion the Challenges , a nonprofit foundation committed to helping inspire and motivate stroke survivors and their families to persevere during this life challenge.
  • "I am humbled and grateful to be honored with the 2022 Stroke Survivor Hero Award," said Deb Shaw.
  • Champion the Challenges has also provided nearly 1,000 quick-read self-help booklets for free to area hospitals and stroke survivors.
  • Champion the Challenges is a non-profit foundation with a mission to help stroke survivors, therapists, family, and friends to reimagine stroke rehabilitation.